Who are in the management team of Parmax Pharma?

As of March 2022, the management team of Parmax Pharma includes Umang Alkesh Gosalia as Managing Director, Pramay Amritlal Chhatra and Ami R Shah as Non-Executive & Independent Directors, and Yash Vora as Company Secretary & Compliance Officer.

As of March 2022, the management team of Parmax Pharma includes the following individuals:<BR><BR>1. Umang Alkesh Gosalia - Managing Director<BR>2. Pramay Amritlal Chhatra - Non-Executive & Independent Director<BR>3. Ami R Shah - Non-Executive & Independent Director<BR>4. Yash Vora - Company Secretary & Compliance Officer<BR><BR>Umang Alkesh Gosalia is the Managing Director, while the other members serve in non-executive and compliance roles.

Has Parmax Pharma declared dividend?

No Dividend History Available

Who are the peers of the Parmax Pharma?

Parmax Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Venmax Drugs, Decipher Labs, Span Divergent, and Saroja Pharma. Parmax Pharma has below average management risk and capital structure, with a 1-year return of 37.99%.

Peers: The peers of Parmax Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Venmax Drugs, Decipher Labs, Span Divergent, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Saroja Pharma In, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is attributed to Parmax Pharma and Decipher Labs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Parmax Pharma, Saroja Pharma In, and Decipher Labs. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is attributed to Parmax Pharma, Venmax Drugs, Decipher Labs, and Span Divergent.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Decipher Labs has the lowest at -37.27%. Parmax Pharma's 1-year return of 37.99% is lower than that of Divi's Lab. but higher than Decipher Labs. Additionally, the six-month return is negative for Venmax Drugs, Decipher Labs, and Span Divergent.

Is Parmax Pharma overvalued or undervalued?

As of February 1, 2024, Parmax Pharma's valuation has downgraded to risky, with negative financial ratios indicating it is overvalued compared to peers like Cipla and Dr. Reddy's, and its stock has underperformed with a year-to-date return of -10.06%.

As of 1 February 2024, the valuation grade for Parmax Pharma has moved from attractive to risky, indicating a significant downgrade in its perceived value. The company is currently assessed as overvalued, with a PE ratio of -14.03, an EV to EBIT of -21.92, and a Price to Book Value of -7.19. These ratios suggest that the company is struggling financially, as reflected in its negative return on capital employed (ROCE) of -13.70% and negative return on equity (ROE).<BR><BR>In comparison to its peers, Parmax Pharma stands out negatively against companies like Cipla Ltd., which has a PE ratio of 22.99 and an EV to EBITDA of 15.93, and Dr. Reddy's Laboratories Ltd., with a PE of 19.49 and an EV to EBITDA of 12.87. The stark contrast in valuation metrics underscores the challenges Parmax Pharma faces within the pharmaceuticals and biotechnology industry. Additionally, the company's recent stock performance has been disappointing, with a year-to-date return of -10.06%, significantly lagging behind the Sensex's 5.58% return.

What is the technical trend for Parmax Pharma?

As of June 3, 2025, Parmax Pharma's technical trend is mildly bullish, supported by daily moving averages and monthly Bollinger Bands, despite some caution from weekly MACD and Dow Theory indicators.

As of 3 June 2025, the technical trend for Parmax Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, primarily driven by the daily moving averages indicating mild bullishness, while the monthly Bollinger Bands show a mildly bullish trend. However, the weekly MACD and Dow Theory are both mildly bearish, indicating some caution. The KST remains bullish on both weekly and monthly time frames, providing some support to the overall mildly bullish outlook. The RSI shows no signals in both weekly and monthly time frames, suggesting a lack of momentum. Overall, while there are mixed signals, the prevailing trend is mildly bullish.

What does Parmax Pharma do?

Parmax Pharma Ltd specializes in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO) within the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 48 Cr and a net loss of 15 Cr, with a market cap of INR 16 Cr.

Overview:<BR>Parmax Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry, focusing on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO).<BR><BR>History:<BR>Incorporated in November 1994, Parmax Pharma Ltd was promoted by Jayantilal S Dhol, Purushottam J Bhalodi, and Prabhudas D Hansalpara. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 48 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -15 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 16 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.82 <BR>Return on Equity: 51.26% <BR>Price to Book: -7.90 <BR><BR>Contact Details:<BR>Address: Plot No 20 Survey No 52, Tal Kotda Sangani Hadamtala Rajkot Gujarat : 360311 <BR>Tel: 91-2827-270534/535 <BR>Email: info@parmaxpharma.com <BR>Website: http://www.parmaxpharma.com

Who are the top shareholders of the Parmax Pharma?

The top shareholders of Parmax Pharma are Alkesh Mahasukh Gopani with 17.92%, and Gosalia Meena Alkesh with 12.69%. Individual investors hold a combined 63.1%, with no institutional holdings or pledged shares reported.

The top shareholders of Parmax Pharma include Alkesh Mahasukh Gopani, who holds the highest promoter stake at 17.92%. The highest public shareholder is Gosalia Meena Alkesh, with a holding of 12.69%. Additionally, individual investors collectively own 63.1% of the company. There are no institutional holdings or pledged promoter shares reported.

How big is Parmax Pharma?

As of 24th July, Parmax Pharma Ltd has a market capitalization of 15.00 Cr, with recent net sales of 28.21 Cr and a net loss of 2.09 Cr over the last four quarters. Shareholder's funds are valued at 0.07 Cr, and total assets amount to 15.33 Cr.

As of 24th July, <BR><BR>Market Cap: Parmax Pharma Ltd has a market capitalization of 15.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest four quarters is 28.21 Cr. The sum of Net Profit for the same period shows a loss of 2.09 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2024. Shareholder's Funds are valued at 0.07 Cr, and Total Assets amount to 15.33 Cr.

When is the next results date for Parmax Pharma?

The next results date for Parmax Pharma is 14 August 2025.

The next results date for Parmax Pharma is scheduled for 14 August 2025.

Are Parmax Pharma latest results good or bad?

Parmax Pharma's latest results are concerning, with a 43.96% year-on-year decline in net sales to Rs 6.77 crore and both profit before tax and profit after tax at their lowest levels, indicating significant challenges in revenue generation and profitability.

Parmax Pharma's latest financial results for the quarter ending June 2025 indicate a challenging situation for the company. The net sales have significantly decreased by 43.96% year-on-year, totaling Rs 6.77 crore, which reflects ongoing difficulties in generating revenue. Additionally, both profit before tax (PBT) and profit after tax (PAT) have reached their lowest points, with PBT at Rs -0.77 crore and PAT at Rs -0.76 crore, marking a consistent decline over the last five quarters.<BR><BR>Overall, these results suggest that Parmax Pharma is facing substantial struggles in terms of both sales and profitability, indicating a tough environment ahead for the company.

How has been the historical performance of Parmax Pharma?

Parmax Pharma has experienced fluctuating financial performance, with net sales increasing from 11.05 Cr in Mar'24 to 28.20 Cr in Mar'25, but facing ongoing profitability challenges, including negative profits after tax of -2.09 Cr in Mar'25 and deteriorating reserves of -6.44 Cr. Despite revenue growth, the company struggles with liquidity and a rising debt burden.

Answer:<BR>The historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Parmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriorating financial position. Total assets increased to 18.56 Cr in Mar'25 from 15.33 Cr in Mar'24, while total liabilities also rose to 18.56 Cr in Mar'25 from 15.33 Cr in Mar'24, indicating a growing debt burden. Cash flow from operating activities remained stagnant at 0.00 Cr in Mar'24 and Mar'23, highlighting liquidity issues. Overall, while there are signs of revenue growth, Parmax Pharma continues to face significant profitability and financial stability challenges.

Should I buy, sell or hold Parmax Pharma?

Which are the latest news on Parmax Pharma?

Why is Parmax Pharma falling/rising?

As of 03-Dec, Parmax Pharma Ltd's stock price is rising to 33.79, reflecting a short-term recovery after previous declines and outperforming its sector. However, concerns about declining investor participation and longer-term performance metrics remain.

As of 03-Dec, Parmax Pharma Ltd's stock price is rising, currently at 33.79, with a change of 0.63 (1.9%) upwards. This increase can be attributed to a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, it has outperformed its sector by 1.91% today, indicating a positive movement relative to its peers.<BR><BR>In the context of recent performance, the stock has shown a significant increase of 8.65% over the past week, contrasting with a decline of 0.59% in the Sensex during the same period. However, it is important to note that the stock has experienced a decline of 2.76% over the past month and a more substantial drop of 23.64% year-to-date, which reflects a longer-term downward trend.<BR><BR>Despite the current rise, there are concerns regarding falling investor participation, as evidenced by a delivery volume of 207 on December 2, which has decreased by 66.31% compared to the 5-day average. This decline in participation could impact future price movements. Furthermore, while the stock is currently above its 5-day, 20-day, and 50-day moving averages, it remains below its 100-day and 200-day moving averages, suggesting mixed signals regarding its longer-term performance.<BR><BR>Overall, the current rise in Parmax Pharma's stock price is primarily driven by a short-term recovery after recent declines and relative outperformance against its sector, despite ongoing challenges in investor participation and longer-term performance metrics.